The smart solution for preclinical development

Depend on Noble Life Sciences as your partner for high-quality, detail-oriented R&D.

Contact Us Today »

NOBLE AWARDS $25,000 IN RESEARCH SERVICES TO SYNAM VACCINE

Posted: April 16th 2013

Noble Awards $25,000 in Research Services to SynAm Vaccine

Contributes Drug Development Services through InvestMaryland Business Competition

Noble Life Sciences, Inc. (Gaithersburg, MD) awarded $25,000 of its drug development contract research services to SynAm Vaccine (Rockville, MD) as part of the InvestMaryland Challenge business competition.  Organized by the state of Maryland, the business plan competition awards $300,000 in grants and $125,000 in business services to early-stage companies in life science and high tech.  The goal of the program is to build a pipeline of companies for growth in Maryland. 

Noble will provide SynAm $25,000 worth of its preclinical development services including a best-in-class vivarium, cell and animal disease models, preclinical protein and monoclonal antibody production, and biomarker selection and validation. Noble’s scientific team provides top-tier leadership and direction to help optimize development strategies and executes research plans with quality, speed and integrity. For more information, please see www.noblelifesci.com

SynAm Vaccine's mission is to eradicate pneumococcal diseases — pneumonia, middle ear infections, and meningitis — with the world's first universal vaccine. Pneumococcal diseases are the leading cause of serious illness in children and adults throughout the world and account for more deaths than all other vaccine-preventable bacterial diseases combined.

« Back to News